Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New balloon device shows promise in clearing hardened heart blockages

NCT ID NCT06358508

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a very small balloon catheter (Sapphire 3) in 170 people with severely blocked heart arteries (chronic total occlusions). The balloon was used to open the blockage before placing a stent. The main goal was to see if the device could be safely delivered, inflated, and removed without causing serious damage. Results focused on immediate success and safety during the hospital stay.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

170 people

The number who actually took part.

Started

Nov 2024

Finished

Oct 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Clinical Inclusion Criteria: 1. Subject is ≥ 18 years of age. 2. Subject or a legally authorized representative must provide written informed consent prior to any study related procedures. 3. Subject must agree not to participate in any other clinical study during hospitalization for the index procedure that would interfere with the endpoints of this study. 4. Subjects must have a single or double vessel coronary artery disease and clinical evidence of ischemic heart disease, such as stable / unstable angina or silent ischemia attributed to the CTO target vessel and is scheduled for clinically indicated percutaneous revascularization with planned stent placement during this index procedure. Angiographic Inclusion Criteria 5. Subject must have at least one de novo or restenotic lesion in native coronary arteries with Thrombolysis In Myocardial Infarction (TIMI) flow grade of 0 or 1 and is estimated to be at least 3 months in duration by clinical, angiographic, or electrocardiographic criteria. 6. A maximum of two lesions, including at least one target lesion, in up to two coronary arteries. 7. Treatment of non-target lesion, if any, must be completed prior to treatment of target lesion and must be deemed a clinical angiographic success by visual assessment. 8. The Target lesion is intended for stent placement during this index procedure. Clinical Exclusion Criteria: 1. Subject with a known hypersensitivity or contraindication to aspirin, heparin, bivalirudin, anti-platelet medications, or sensitivity to contrast media which cannot be adequately pre-medicated. 2. Evidence of acute myocardial infarction (MI) within 72 hours prior to the intended treatment defined as CK-MB or troponin greater than 1X the upper limit of normal (ULN). 3. Subject with known pregnancy or is nursing. Women of child- bearing potential should have a documented negative pregnancy test within 7 days before index procedure. 4. Planned or actual target lesion treatment prior to the use of the Study Device with an unapproved device, atherectomy, laser, cutting balloon or thrombectomy during the index procedure. 5. A serum creatinine level \> 2.0 mg/dl within seven days prior to index procedure. 6. Cerebrovascular accident (CVA) within the past 6 months. 7. Active peptic ulcer or active gastrointestinal (GI) bleeding within the past 6 months. 8. Subject has a known left ventricular ejection fraction (LVEF) \<30% (LVEF may be obtained at the time of the index procedure if the value is unknown, if necessary). Angiographic Exclusion Criteria 9. More than two lesions requiring treatment. 10. Unprotected left main coronary artery disease. (Greater than 50% diameter stenosis). 11. Coronary artery spasm of the target vessel in the absence of a significant stenosis. 12. Target lesion with angiographic presence of probable or definite thrombus of TIMI thrombus grade 3 or 4. 13. By visual estimation, target lesion involves a bifurcation requiring treatment with more than one stent or pre-dilatation of a side branch \>2.25 mm in diameter. 14. Previous coronary interventional procedure of any kind within the 30 days prior to the procedure in the target vessel. 15. Target vessel with a patent bypass graft from prior coronary bypass surgery. 16. Previous stenting (drug-eluting or bare metal) in the target vessel unless all the following conditions are met: * It has been at least 9 months since the previous stenting. * That target lesion is at least 15 mm away from the previously placed stent. Total occlusions involving an in-stent segment are excluded. * The previously stented segment (stent plus 5 mm on either side) has no more than 40% diameter stenosis. 17. Non-target lesion to be treated during the index procedure meets any of the following criteria: * Located within a bypass graft (venous or arterial) * Left main location * Chronic total occlusion (CTO) * Is moderately to severely calcified. * Involves a bifurcation (e.g., bifurcations requiring treatment with more than 1 stent) * Treatment not deemed a clinical angiographic success

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Arteriosclerosis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Atlanta VA Health Care System

    Decatur, Georgia, 30033, United States

  • Brigham and Women's Hospital Heart and Vascular Center

    Boston, Massachusetts, 02115, United States

  • Emory St. Joseph's Hospital

    Atlanta, Georgia, 30342, United States

  • Emory University Hospital

    Atlanta, Georgia, 30322, United States

  • Emory University Hospital Midtown

    Atlanta, Georgia, 30308, United States

  • Henry Ford Health System

    Detroit, Michigan, 48202, United States

  • Hospital Clinico Universitario de Valladolid

    Valladolid, 47003, Spain

  • Hospital Universitari de Bellvitge

    Barcelona, 08907, Spain

  • Massachusetts General Hospital

    Boston, Massachusetts, 02114, United States

  • Minneapolis Heart Institute Foundation

    Minneapolis, Minnesota, 55407, United States

  • Piedmont Heart Institute

    Atlanta, Georgia, 30309, United States

  • Stanford Health Care

    Stanford, California, 94305, United States

  • Torrance Memorial Medical Center

    Torrance, California, 90505, United States

  • University of Washington

    Seattle, Washington, 98195, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.